Summary
CPT-11, a new derivative of camptothecin, was effective against tumor cells, especially vincristine (VCR)-and adriamycin (ADM)-resistant P388 leukemia, compared to either VCR or ADM. The drug showed superior chemotherapeutic effects over VCR and ADM in sensitive P388 leukemia-bearing mice, and was also effective in VCR-and ADM-resistant P388 leukemia-bearing mice. These latter survival advantages with CPT-11 were almost equal to those obtained by CPT-11 against sensitive P388 leukemia. CPT-11 was found to be effective against human tumor cells, especially various pleiotropically drug-resistant human tumor lines, compared to VCR and ADM. CPT-11 should be considered for further development as a new chemotherapeutic agent potentially effective against pleiotropically drug-resistant tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiyama S, Fojo A, Hanover J, Pastan I (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genet 11: 117
Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I (anti-tumor agent/camptothecin-11/leukemia cells). Proc Natl Acad Sci USA (in press)
Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070
Creaven PJ, Allen LM, Muggia FM (1972) Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573
Danø K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466
Gallo RC, Whang-peng J, Adamson RH (1971) Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789
Gottlieb JA, Luce JK (1972) Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103
Inaba M, Kobayashi H, Sakurai Y, Johnson RK (1979) Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39: 2200
Kunimoto T, Nitta K, Takeuchi M, Uehara N, Baba H, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of a new camptothecin derivative, sn-22, against various murine tumors. J Pharmacobiodyn 10: 148
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95
Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56: 515
Nitta K, Yokokura T, Sawada S, Takeuchi M, Tanaka T, Uehara N, Baba H, Kunimoto T, Miyasaka T, Mutai M (1985) Antitumor activity of a new derivative of camptothecin. In: Ishigami J (ed) Recent advances in chemotherapy, Anticancer Section I, Proceedings of the 14th International Congress of Chemotherapy. University of Tokyo Press, Tokyo
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1979) Comparison of cytotoxic effect and cellular uptake of 1-β-D-arabinofuranosylcytosine and its N4-acyl derivatives, using cultured KB cells. Cancer Res 39: 1068
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967
Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y (1983) Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers1. Cancer Res 43: 2905
Tsuruo T, Oh-hara T, Saito H (1986) Characteristics of vincristine resistance in vincristine resistant human myelogenous leukemia K562. Anticancer Res 6: 637
Tsuruo T, Saito H, Kawabata H, Oh-hara T, Hamada H, Utakoji T (1986) Characteristics and mechanisms of resistance in human myelogenous leukemia K562 resistant to adriamycin. Jpn J Cancer Res 77: 682
Tsuruo T, Hamilton TC, Louie KG, Ozols RF (1986) Collateral susceptibility of adriamycin-, melphalan-, and cisplatinresistant human ovarian tumor cells to bleomycin. Jpn J Cancer Res 77: 941
Tsuruo T, Oh-hara T, Iida H, Tsukagoshi S, Sato Z, Matsuda I, Iwasaki S, Okuda S, Shimizu F, Sasagawa K, Fukami M, Fukuda K, Arakawa M (1986) Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res 46: 381
Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant antitumor agents: 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 83: 3888
Yaw-Huei H, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsuruo, T., Matsuzaki, T., Matsushita, M. et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21, 71–74 (1988). https://doi.org/10.1007/BF00262744
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262744